Rep. Julie Johnson Sells Off Shares of Johnson & Johnson (NYSE:JNJ)

Representative Julie Johnson (D-Texas) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Xcel Energy (NASDAQ:XEL) on 12/18/2025.

Johnson & Johnson Trading Down 0.3%

Shares of JNJ opened at $218.81 on Friday. The business’s 50-day moving average price is $205.82 and its 200 day moving average price is $186.95. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. The stock has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s dividend payout ratio (DPR) is 50.19%.

Institutional Investors Weigh In On Johnson & Johnson

A number of hedge funds and other institutional investors have recently made changes to their positions in JNJ. Abich Financial Wealth Management LLC bought a new stake in Johnson & Johnson in the third quarter worth $26,000. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter worth about $27,000. Clayton Financial Group LLC acquired a new stake in shares of Johnson & Johnson in the third quarter worth about $28,000. Semmax Financial Advisors Inc. boosted its stake in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after acquiring an additional 72 shares in the last quarter. Finally, GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the 2nd quarter valued at about $35,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

JNJ has been the topic of several research analyst reports. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. The Goldman Sachs Group raised their target price on Johnson & Johnson from $213.00 to $240.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Morgan Stanley raised their price objective on Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a research report on Friday, December 12th. Finally, Bank of America upped their target price on Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Four investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $213.33.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.